09/24/2008 Katie Hood Appointed to NINDS Council
Katie Hood, chief executive officer of The Michael J. Fox Foundation for Parkinson’s Research, is one of four new members appointed to the NINDS Council, the major advisory panel to The National Institute of Neurological Disorders and Stroke (NINDS). She will serve through July 2012.
The Michael J. Fox Foundation announced today that actor Ryan Reynolds will serve as the first Celebrity Chair of Team Fox, the Foundation’s grassroots fundraising initiative.
The Michael J. Fox Foundation today announced that it would award Santa Monica-based biotech ArmaGen Technologies, Inc., up to $1 million if all milestones are met to take practical steps toward developing a “Trojan horse” delivery technology for the treatment of Parkinson’s disease.
MJFF funded 15 high-risk, high-reward Parkinson’s disease research projects under Rapid Response in the first half of the year. Applications are still being accepted, and a total of $2 million in Rapid Response awards is expected by year’s end.
Latest awards under Therapeutics Development Initiative bring MJFF’s current active industry collaborations to 23; next industry-only deadline January 20, 2009
The Michael J. Fox Foundation for Parkinson’s Research today announced approximately $2.4 million in total funding to nine research teams under its Target Validation initiative.
06/26/2008 LPGA Golfer Jane Park to Raise Funds for Michael J. Fox Foundation for Parkinson's Research
Golf pro Jane Park, playing in the U.S. Women's Open, will donate a portion of her earnings to The Michael J. Fox Foundation to help fund critically needed Parkinson’s research.
06/03/2008 Michael J. Fox Foundation Commits Up to $2 Million to Visualize Alpha-Synuclein Protein in the Brain
Funding to be issued under second round of Critical Challenges in Parkinson’s Disease initiative
The Michael J. Fox Foundation announced a $5.6-million award to drive a Phase 2 clinical trial to investigate the potential of inosine — a naturally occurring chemical that gives rise to urate in the body — to slow or stop the progression of Parkinson’s disease.
04/07/2008 Registration Open for Annual PD Therapeutics Conference
The Michael J. Fox Foundation has opened registration for its annual PD Therapeutics Conference to be held in Chicago, Illinois, on September 15, 2008.
The Michael J. Fox Foundation for Parkinson’s Research seeks applications for its $10-million 2008 Therapeutics Development Initiative. The 2008 program includes a special funding track for academic researchers.
03/25/2008 Michael J. Fox Foundation Commits Up to $2 Million to Improve Drug Delivery for Parkinson's Disease
The Michael J. Fox Foundation for Parkinson’s Research announced the launch of a new funding program, Improving Delivery of Parkinson’s Disease Therapeutics to the Brain.
The Foundation has announced a $1-million new Web-based Clinical Assessment Program to drive the creation and testing of Web-based tools that would allow any patient with a personal computer and an Internet connection to participate in clinical research from the comfort of their own home.
Michael J. Fox Foundation for Parkinson’s Research today announced the 2008 launch of its annual Clinical Intervention Awards.
Four industry research projects targeted as part of innovative Therapeutics Development Initiative.
Approximately $2 million in total funding was awarded to seven research studies aiming to advance the ability of the Parkinson’s research field, and drug makers, to therapeutically target two genes — LRRK2 and alpha-synuclein.
Founding gift for “The Grove Circle,” honoring planned gift donors,
reflects shared commitment to transformative approach
A research team funded under the Foundation's LEAPS (Linked Efforts to Accelerate Parkinson's Solutions) initiative will work to optimize a small interfering RNA (siRNA)-based therapeutic that could slow or stop the progression of Parkinson’s disease by reducing expression of the protein alpha-synuclein.
